CANCER IMMUNOTHERAPY: NEW APPLICATIONS IN UROLOGIC ONCOLOGY: Edited by Maria De Santis and Matthew D. GalskyCancer immunotherapy new applications in urologic oncologyMullane, Stephanie A.; Bellmunt, JoaquimAuthor Information Bladder Cancer Center, Dana-Farber Cancer Institute/Harvard Medical School, Boston, Massachusetts, USA Correspondence to Joaquim Bellmunt, Bladder Cancer Center, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA. E-mail: [email protected] Current Opinion in Urology: November 2016 - Volume 26 - Issue 6 - p 556-563 doi: 10.1097/MOU.0000000000000337 Buy Metrics Abstract Purpose of review Immunotherapy in urological cancer has made substantial progress during the last 20 years, but recent advances in immunotherapy have completely transformed the present treatment landscape. In this review, we summarize major clinical achievements of immunotherapy in genitourinary cancers, as well as address potential new directions for these therapies, including new agents, combinations, and biomarkers. Recent findings Recently, nivolumab and atezolizumab have joined sipuleucel-T as Food and Drug Administration-approved therapies in urological malignancies. Additional checkpoint inhibitors and vaccines are being tested in clinical trials. Furthermore, significant work has been done exploring predictors of response to therapy. Summary Immunotherapy has changed the treatment of urologic malignancies. New immunotherapies and novel combinations will continue to create new treatment options in urologic tumors. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.